loader image
Tuesday, April 22, 2025
87.7 F
McAllen
We Welcome your Press Release
- Advertisement -

Post-Exposure Prophylactic Use of Monoclonal Antibodies

Translate to Spanish or other 102 languages!

The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. Image for illustration purposes.
The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Edinburg, TX – Monoclonal antibody infusion has been used quite extensively in treating mild-moderated SARS-CoV-2 infection. The primary objective of this treatment is to prevent the progression of disease to a severe stage requiring hospitalization. At DHR Health and DHR Health Institute for Research & Development, we have infused REGEN-COV monoclonal antibody to over 500 patients with mild-moderate SARS-CoV-2 infection with very satisfactory outcome. This included adults, children and pregnant women who were at high risk for developing severe COVID-19 disease.

“We are embarking on a new project that is both FDA and IRB-approved to infuse monoclonal antibodies to asymptomatic high-risk individuals who are COVID-19 negative but have been exposed to a COVID-19 positive patient” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “The purpose of this initiative is to prevent the development of SARS-CoV-2 infection in qualified adults and children 12 years of age or over who are exposed to a COVID-19 positive patient for at least 15 minutes in a 24-hour period”.

The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. To learn more about who would qualify for this treatment, please visit this website:https://dhrresearch.org/wp-content/uploads/2021/08/CHECKLIST-08-08-2021-1.pdf  or call the post-exposure prophylaxis hotline (956) 362-2357 (9:00 a.m. – 5:00 p.m.; M-F) for more information.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Steps For Stroke Challenge, May 17th-23rd

Taking place May 17-23, the 50,000-step challenge aims to get the...

DHR Health Welcomes Dr. Juan M. Ortiz

Mega Doctor News Brownsville and Rio Grande City, Texas - DHR Health is...

STHS Children’s Special Meet & Greet with Pediatric Patients, April 22nd

Mega Doctor News From human protagonists like Snow White, Alladin and Cinderella and...

Educating The Community About Parkinson’s Disease, April 27th

Mega Doctor News In the United States, about one million people are...
- Advertisement -
×